Agios Pharmaceuticals AGIO

$34.94 +3.62 (11.56%)

Valuation

Market cap
1,869,866,000
Revenue TTM
$54,030,000
Net income TTM
$-412,780,000
PE ratio
0.00
Forward PE
—
Profit margin
-763.98%
Debt to equity
0.00

Trading

Volume
1,209,799
Avg volume
1,032,536
Day's range
$31.61 – $35.03
Shares out
59,702,000
Stochastic %K
52%
Beta
0.63
Analysts
Strong Sell
Price target
$44.44

Price

Company profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disea...

Show more

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 649 8600
Website
https://www.agios.com
Address
88 Sidney Street, Cambridge, United States

Latest news

Stocktwits

topstockalerts Oct 19, 5:42 PM
$AGIO the market seems to want this higher, plain and simple.
0 replies
stu4 Oct 19, 5:37 PM
$AGIO Morgan Stanley’s pump for insiders 105b planned sales and RSU’s available for sale !!! Morgan gets a check from Goff, who will sell on this pump as well A freek show
0 replies
StocktwitsNews Oct 19, 9:43 AM
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings $GSK $INO $AGIO $SUNPHARMA.NSE https://stocktwits.com/news/equity/markets/gsk-inovio-agios-sun-pharma-fda-decision-calendar-october/cZx8jI5RBML
0 replies
BiotechSwings Oct 18, 10:25 PM
Next 3 weeks on the FDA calendar and it is not crowded. that is kind of the point Oct 26 $IONS bepirovirsen for chronic hepatitis B, B Well trials already showed functional cure after treatment stopped Oct 30 $INO INO 3107 for recurrent respiratory papillomatosis, accelerated approval path and inspections already done Nov 1 $AGIO mitapivat for sickle cell disease, a Sunday date so Friday is the practical window quiet on both sides of that little cluster imo. nobody is loud about any of these yet and yes, every one of these dates traces back to a company release or an SEC filing, not calendar gossip
1 replies
Market_Pulse_Report Oct 18, 12:23 PM
$AGIO $BBIO $SMMT $CAPR $INO
1 replies
Market_Pulse_Report Oct 16, 7:13 PM
6 Biotech Stocks Facing FDA Decisions: 3 to Watch, 3 to Avoid COGT $AGIO $BBIO $SMMT $CAPR $INO https://youtu.be/_m7Qx7OA5vM
2 replies
Merlintrader Oct 9, 9:14 PM
Sickle Cell: Progress at $AGIO $CRSP $BEAM $NVO Higher hemoglobin, fewer painful crises and durable benefit are different measures of progress. Here is how the evidence compares. https://www.merlintrader.com/sickle-cell-measures-progress-agio-crsp-beam-nvo/
0 replies
stu4 Oct 6, 12:05 PM
$AGIO when the past CEO, now Chairman of the board Bought 40,000 shares @$30 , on a secondary offering in 2019 , and still it sits at $30 ….an investor has to believe, that the board itself , as well as the past CEO , lacks intelligence to run a company . If you don’t believe me , ask Alex Karp !!!
0 replies